GM-CSF Protein (AA 18-144)

Produktnummer ABIN2181169

Produktdetails

Target: GM-CSF (CSF2) (Colony Stimulating Factor 2 (Granulocyte-Macrophage) (CSF2))

Protein-Typ: Recombinant

Biologische Aktivität: Active

Proteineigenschaft: AA 18-144

Spezies: Human

Quelle: HEK-293 Cells

Marke: ActiveMax®

Sequenz: AA 18-144

Produktmerkmale: This protein carries no "tag". The protein has a calculated MW of 14.5 kDa. The protein migrates as 16-26 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Reinheit: >95 % as determined by SDS-PAGE.

Sterilität: 0.22 μm filtered

Endotoxin-Niveau: Less than 0.1 EU per μg by the LAL method.

Anwendungsinformationen

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Lyophilized

Buffer: PBS, pH 7.4

Handhabung: Please avoid repeated freeze-thaw cycles.

Lagerung: -20 °C

Informationen zur Lagerung: No activity loss was observed after storage at: In lyophilized state for 1 year (4 °C), After reconstitution under sterile conditions for 3 months (-70 °C).

Referenzen

Huang, Yi, Hu, Du, Wang, Ye, Su, Kijlstra, Yang: "Linoleic acid inhibits in vitro function of human and murine dendritic cells, CD4+T cells and retinal pigment epithelial cells." in: Graefe's archive for clinical and experimental ophthalmology, (2020) (PubMed).

He, Wang, Su, Deng, Ye, Huang, Yuan, Aize, Li, Yang: "Decreased expression of A20 is associated with ocular Behcet's disease (BD) but not with Vogt-Koyanagi-Harada (VKH) disease." in: The British journal of ophthalmology, Vol. 102, Issue 8, pp. 1167-1172, (2019) (PubMed).

Qiu, Yu, Zhu, Ye, Deng, Su, Cao, Yuan, Kijlstra, Yang: "Hypermethylation of Interferon Regulatory Factor 8 (IRF8) Confers Risk to Vogt-Koyanagi-Harada Disease." in: Scientific reports, Vol. 7, Issue 1, pp. 1007, (2017) (PubMed).

Antigendetails

Target: GM-CSF (CSF2) (Colony Stimulating Factor 2 (Granulocyte-Macrophage) (CSF2))

Andere Bezeichnung: GM-CSF (CSF2 Produkte)

Synonyme: GMCSF Protein, GM-CSF Protein, CSF2 Protein, Csfgm Protein, Gm-CSf Protein, MGI-IGM Protein, Gm-csf Protein, Gmcsf Protein, CSF Protein, colony stimulating factor 2 Protein, colony stimulating factor 2 (granulocyte-macrophage) Protein, CSF2 Protein, Csf2 Protein

Hintergrund: Granulocyte-macrophage colony-stimulating factor (GM-CSF) is also known as Colony stimulating factor 2 (granulocyte-macrophage), is a cytokine initially characterized by its ability to induce colonies of granulocytes and macrophages from myeloid progenitor cells, and is secreted by macrophages, T cells, mast cells, endothelial cells and fibroblasts. GM-CSF is a cytokine that functions as a white blood cell growth factor. GM-CSF stimulates stem cells to produce granulocytes (neutrophils, eosinophils, and basophils) and monocytes. Monocytes exitthe circulation and migrate into tissue, whereupon they mature into macrophages and dendritic cells. Thus, it is part of the immune/inflammatory cascade, by which activation of a small number of macrophages can rapidly lead to an increase in their numbers, a process crucial for fighting infection. The active form of the protein is found extracellularly as a homodimer. Human GM-CSF glycosylated in its mature form. As a part of the immune/inflammatory cascade, GM-CSF promotes Th1 biased immune response, angiogenesis, allergic inflammation, and the development of autoimmunity, and thus worthy of consideration for therapeutic target. GM-CSF has also recently been evaluated in clinical trials for its potential as a vaccine adjuvant in HIV-infected patients. The preliminary results have been promising. GM-CSF is also used as a medication to stimulate the production of white blood cells following chemotherapy.

Molekulargewicht: 14.5 kDa

NCBI Accession: NP_000749

Pathways: JAK-STAT Signalweg, Cellular Response to Molecule of Bacterial Origin